Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion

Elena M. Stoffel, Shannon E. McKernin, Randall Brand, Marcia Canto, Michael Goggins, Cassadie Moravek, Arun Nagarajan, Gloria M. Petersen, Diane M. Simeone, Matthew Yurgelun, Alok A. Khorana

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

PURPOSE: An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies of systematic reviews and selected seminal articles and contributions from Expert Panel members' curated files. PROVISIONAL CLINICAL OPINION All: patients diagnosed with pancreatic adenocarcinoma should undergo assessment of risk for hereditary syndromes known to be associated with an increased risk for pancreatic adenocarcinoma. Assessment of risk should include a comprehensive review of family history of cancer. Individuals with a family history of pancreatic cancer affecting two first-degree relatives meet criteria for familial pancreatic cancer (FPC). Individuals (cancer affected or unaffected) with a family history of pancreatic cancer meeting criteria for FPC, those with three or more diagnoses of pancreatic cancer in same side of the family, and individuals meeting criteria for other genetic syndromes associated with increased risk for pancreatic cancer have an increased risk for pancreatic cancer and are candidates for genetic testing. Germline genetic testing for cancer susceptibility may be discussed with individuals diagnosed with pancreatic cancer, even if family history is unremarkable. Benefits and limitations of pancreatic cancer screening should be discussed with individuals whose family history meets criteria for FPC and/or genetic susceptibility to pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)153-164
Number of pages12
JournalJournal of Clinical Oncology
Volume37
Issue number2
DOIs
StatePublished - Jan 10 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion'. Together they form a unique fingerprint.

Cite this